GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Handa Pharmaceuticals Inc (ROCO:6620) » Definitions » Financial Strength

Handa Pharmaceuticals (ROCO:6620) Financial Strength : 10 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Handa Pharmaceuticals Financial Strength?

Handa Pharmaceuticals has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Handa Pharmaceuticals Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Handa Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2024 was 1,039.45. Handa Pharmaceuticals's debt to revenue ratio for the quarter that ended in Jun. 2024 was 0.04. As of today, Handa Pharmaceuticals's Altman Z-Score is 24.44.


Competitive Comparison of Handa Pharmaceuticals's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Handa Pharmaceuticals's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's Financial Strength distribution charts can be found below:

* The bar in red indicates where Handa Pharmaceuticals's Financial Strength falls into.


;
;

Handa Pharmaceuticals Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Handa Pharmaceuticals's Interest Expense for the months ended in Jun. 2024 was NT$-0.1 Mil. Its Operating Income for the months ended in Jun. 2024 was NT$91.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$31.2 Mil.

Handa Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2024 is

Interest Coverage=-1*Operating Income (Q: Jun. 2024 )/Interest Expense (Q: Jun. 2024 )
=-1*91.472/-0.088
=1,039.45

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Handa Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Handa Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Jun. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.738 + 31.153) / 862.132
=0.04

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Handa Pharmaceuticals has a Z-score of 24.44, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 24.44 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Handa Pharmaceuticals  (ROCO:6620) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Handa Pharmaceuticals has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.


Handa Pharmaceuticals Financial Strength Related Terms

Thank you for viewing the detailed overview of Handa Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Handa Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.

Handa Pharmaceuticals Headlines

No Headlines